INTRODUCTION

Pediatric noninfectious uveitis
Noninfectious pediatric uveitis is an inflammatory eye disease that can lead to ocular complications and vision loss. It is most often associated with juvenile idiopathic arthritis (JIA), but can be observed in other autoimmune conditions like Behcet's disease or sarcoidosis. Idiopathic uveitis, uveitis without associated systemic illness, is at least as common as JIA-associated uveitis (JIA-U). Classification is often by anatomic location with anterior uveitis being the most common manifestation. Ocular complications are reported in up to 50% of children, vision loss (visual acuity: 20 of 50 or worse) in 25-40%, and legal blindness (visual acuity: 20 of 200 or worse) in up to 25% [1 & ,2 -5] . A chronic course with remission and relapses is characteristic, and many children require long-term immunosuppressive therapy. This review focuses on risk factors for uveitis and severe disease, with an emphasis on anterior uveitis, treatment-related factors, and measurement of visual outcomes.
Risk factors for uveitis development
Similarly to other autoimmune diseases, the cause of uveitis is multifactorial and can include genetic predisposition, environmental triggers, immune system activation, and clinical risk factors.
Genetics
Most genetic studies in pediatric uveitis focus on non-Hispanic white (NHW) children with JIA. Associations are reported with polymorphisms of Human Lymphocyte antigen (HLA) class II genes wherein HLA-DR1 has a protective effect, and there is an increased predisposition in children who carry the HLA-DRB1 Ã 11, HLA-DRB1 Ã 13, and HLA-B27 alleles [6] [7] [8] [9] [10] .
In a cohort of 107 NHW children with oligoarticular and polyarticular rheumatoid factor negative JIA, Angeles-Han [11 & ] examined differences between 60 children with JIA, 47 with JIA-U, and 373 NHW controls. Compared with controls, children with JIA-U who carried both HLA-DRB1 Ã 11 and Ã 13 had a nine-fold increased odds ratio (OR) of developing uveitis [OR, 9 (95% CI 2.8-29), P ¼ <0.001]. When compared with children with JIA alone, those with JIA-U had an eight-fold increased odds [OR, 8.6 (95% CI, 1.0-74.4), P ¼ 0.042], but lost its statistical significance after Bonferroni's correction.
Marrani [12
& ] reported on the association of Nucleotide binding oligomerization domain (NOD)2/Caspase recruit domain gene15 gene in 25 Italian patients with autoimmune chronic uveitis, (18 children -10 JIA, eight idiopathic, and six adults) and 25 age and sex-matched controls. The variant P268S/SNP5 was found in 17 uveitis cases (15 heterozygous and two homozygous) which was statistically different from controls [OR, 4.03 (95% CI 1.2-13.5), P ¼ 0.04].
Further investigation of genetic variants in larger uveitis cohorts is warranted to further elucidate genetic predisposition.
Clinical risk factors
Approximately 10-20% of children with JIA are at risk for uveitis. Those with positive antinuclear antibodies, are young at arthritis diagnosis ( 6 years old), have oligoarticular or polyarticular rheumatoid factor negative JIA, and early in their disease course ( 4 years) are considered high risk. Current screening guidelines recommend monitoring these children every 3-4 months [13] . In 287 children with JIA, 18% with uveitis, Angeles- 
Biomarkers
Potential biomarkers have been examined for early detection of JIA-U, as indicators of active disease, and for targeted therapy [14] .
Hasnoot [15 & ] confirmed the elevated erythrocyte sedimentation rate as a predictor of uveitis in oligoarticular and polyarticular rheumatoid factor negative JIA. Ayuso [16 && ] described the histopathologic and immunohistochemical findings of iris specimens of children who underwent elective trabulectomy and peripheral iridectomy. They examined 31 eyes of 25 patients and six controls with glaucoma but no uveitis. Similarly to earlier histologic studies [17-19] of enucleated eyes and an iridectomy sample in JIA-associated uveitis, plasma cells were abundant. These findings may have implications for treatment strategies targeted to B cells such as rituximab therapy.
Walscheid reported an increase in the S100 subtypes S100A8/A9 and S100A12 levels in both serum and aqueous humor (AqH) of children with autoimmune uveitis [20 && ]. There were 79 patients with oligoarticular JIA-U (89 serum and 17 AqH samples), 24 with idiopathic anterior uveitis (23 serum and 12 AqH), and 24 controls (17 serum and 16 AqH). As elevations occur in active arthritis and active uveitis regardless of cause, S100A8/A9 and S100A12 are likely not disease-specific, but rather a general indication of ongoing inflammation associated with activated neutrophils. Elevated serum S100 levels, which are phagocyte-specific, may be a potential biomarker for ocular inflammation in inactive arthritis.
Another ] reports increased antidense fine speckled 70 kDa antigen (DFS70) antibodies in JIA-U (N ¼ 19) and idiopathic uveitis (N ¼ 7), found in 10.5 and 14.3% of children, respectively, and 11.5% (3 of 26) when combined. Although not statistically significant when compared with 145 healthy children (2.1%), the frequency was increased in comparison with 183 JIA children without uveitis (1.6%).
Discovery of biomarkers that aid in the screening, monitoring of disease activity, and targeted treatment of uveitis could improve final visual outcomes.
Risk factors for severe uveitis
Sight-threatening complications occur in pediatric noninfectious uveitis. Risk factors include a short duration between arthritis and uveitis diagnoses,
KEY POINTS
Novel biomarkers and genetic factors may aid in the screening and monitoring of uveitis and lead to targeted treatment.
Race may be associated with visual outcomes wherein African-American children have increased vision loss and ocular complications.
Refractory uveitis may need escalated therapy beyond TNFi, but there are few data to guide therapy of severe refractory disease.
Reactivation of uveitis after medication discontinuation is high and elucidation of factors that predict remission are needed.
To appropriately measure visual outcomes in children with uveitis, we need to consider other factors apart from the clinical ocular exam.
young age at uveitis onset, male sex, uveitis diagnosed prior to arthritis, and the presence of vision loss or complications at first ophthalmology exam.
Racial associations
Differences in the epidemiology of uveitis based on geographic location are described [23, 24] . For example, in a 10-year study [25] of 107 children with JIA in Oman, there was no development of uveitis. Variations in prevalence may be related to race, especially as race and ethnicity affect development of autoimmune diseases.
Few studies on uveitis focus on African-American children despite distinctions in the prevalence of JIA categories based on race. Approximately 8% of African-American children with JIA develop uveitis, with few descriptions of their visual outcomes [26] [27] [28] [29] . The association of race with visual outcomes was examined by Angeles-Han in 287 JIA children. Fifty-two (18%) developed uveitis, of whom eight (15%) were African-American [1 & ]. Eight children were legally blind, and of these, five were African-American (62%). In addition, African-American children averaged three times more eye complications compared with NHW (P < 0.01). In a larger cohort of 94 children with varied forms of noninfectious uveitis, 28 (30%) were African-Americans [30 & ]. Of the 22 NHW and African-American children with a history of blindness, 18 (82%) were African-American; all eight with bilateral blindness were African-American. At last follow-up, 50% of the African-American children were still blind compared with 25% of NHW. African-American race increased the risk for blindness by 30-fold [OR 31.64 (95% CI 5.94-168.49), P < 0.001], and when analysis was restricted to anterior uveitis only, there was still a 10-fold increased risk of blindness [OR 10.58 (95% CI 1.76-63.75), P < 0.001]. African-American children also had an increased risk of complications [OR 2.21 (95% CI 1.40-3.49), P < 0.001].
Further investigation into the cause of poor visual outcomes in African-American, such as variance in healthcare access, medication adherence, or biologic differences, need more study.
Risk for elevated intraocular pressure Kothari [31 & ] showed that risk factors for increased intraocular pressure (IOP) include IOP in the contralateral eye, and the need for topical (>1 drop prednisolone acetate 1% or equivalent) or intraocular corticosteroids.
Treatment
There are panel recommendations on treatment of noninfectious uveitis based on expert opinion, but no large randomized controlled trials [32, 33] . Initially, topical corticosteroids are used, but in refractory cases, methotrexate and/or biologic therapies, typically tumor necrosis factor a inhibitor (TNFi) drugs such as infliximab or adalimumab, are recommended. A comprehensive set of stepwise treatment algorithms for children with JIA-related uveitis was recently proposed based on an interdisciplinary panel consensus which provides recommendations for use of methotrexate, anti-TNFa agents, abatacept, and tocilizumab [34 & ].
Dexamethasone intravitreal implants are used in intermediate and posterior uveitis with low rates of development of cataracts and increased IOP [35] . Henderson [36 & ] examined data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry, a registry of patients with pediatric rheumatic disease in North America, to examine practice patterns of pediatric rheumatologists. In 646 children with JIA-associated uveitis and 92 with idiopathic uveitis, 80% of children in both groups were treated with a diseasemodifying antirheumatic drugs (DMARD), and approximately 50% with a biologic agent. However, as indication for treatment in children with JIAassociated uveitis was not specified (arthritis or uveitis), medication analysis was restricted to the 92 with idiopathic uveitis. Methotrexate was the most common steroid sparing agent (76%) with equal use of oral and subcutaneous routes, and 53% required a TNFi (infliximab 36, adalimumab 18, golimumab 1). Furthermore, six children needed multiple biologic agents, and two were treated with a biologic without a preceding DMARD [36 & ]. Thus, many children with uveitis need immunosuppressive therapy with greater than half requiring biologics.
Treatment of tumor necrosis factor a inhibitor refractory uveitis
In cases requiring escalation of therapy beyond TNFi agents, there are no large studies to help guide use, rather, small case series exist. Abatacept has been shown to be effective in small case reports and series of children with JIA-associated uveitis. However, Tappeiner [37 & ] retrospectively described an unsustained response to monthly abatacept (10 mg/kg, maximum 750 mg) in 21 children with severe, chronic, and refractory JIA-U treated with steroids, DMARDs (all treated with methotrexate), and at least one TNFi. Ten did not respond and had persistently active uveitis. Of the 11 with response, eight relapsed. Additionally, there were three patients with new onset ocular complications, and five with progression of a preexisting cataract. There was no significant improvement in Best corrected visual acuity. Thus, abatacept did not prove effective in chronic refractory severe uveitis, although only 12 completed 12-month follow-up. Alternatively, Marrani [38] reported on the successful use of abatacept in three children with idiopathic uveitis followed for a range of 18-42 months. All discontinued systemic steroids but two needed ongoing methotrexate.
Miserocchi [39 && ] examined five patients with severe and longstanding oligoarticular JIA-U treated with corticosteroids, DMARDs (methotrexate and/ or cyclosporine), and at least one TNFi and/or abatacept in whom they administered rituximab, an anti-CD20 B-cell monoclonal antibody. Rituximab was dosed as 1000 mg on days 1 and 14 and after 6 months if needed for active arthritis and/or uveitis. Patients were older (ages 16-34 years) with anterior uveitis (n ¼ 5) or anterior and posterior pole complications (N ¼ 3) and a mean uveitis duration of 17.7 AE 5.6 years. At last follow-up (mean followup time 44.75 AE 4.9 months), all patients were in remission, with improvement seen 4 months from first infusion. Systemic corticosteroids were discontinued in six patients, and other immunosuppressants were tapered wherein only two patients used weekly methotrexate. Thus, rituximab may be an alternative treatment option in longstanding severe refractory uveitis.
Uveitis occurrence during treatment
Accurate estimates of the incidence and prevalence of uveitis are challenging as treatment for JIA and uveitis are similar. Underlying systemic therapy for JIA may influence the development of uveitis.
Foeldvari [40 & ] examined the protective effect of methotrexate using the adverse event-reporting system of the German Biologics in Pediatric Rheumatology (BIKER) Registry. They analyzed the number of uveitis events during treatment of JIA. In patients treated with methotrexate and a biologic agent there were fewer uveitis occurrences versus biologic agent alone. Although there was a decreased rate of uveitis in patients on etanercept alone versus adalimumab, there are several confounding factors, including a significant selection bias for treatment.
Tappeiner [41 && ] utilized a German national database to describe the impact of methotrexate on the occurrence of uveitis in a cohort of 3512 JIA patients in whom 431 developed uveitis. Children treated with methotrexate early in the JIA diagnosis had a reduced risk for uveitis development [hazard ratio (HR) 0.29 (95% CI 0.19-0.45), P < 0.001] with the greatest effect seen with the combined use of TNFi and methotrexate [HR 0.10 (95% CI 0.05-0.23), P < 0.001].
Risk of reactivation or relapse
Optimal duration of therapy for uveitis is largely unknown. Treatment with methotrexate is recommended for at least 3 years with delayed withdrawal in younger children as uveitis relapse is high [42, 43] .
Lerman [44] examined 19 children with noninfectious uveitis who discontinued TNFi treatment and factors associated with uveitis relapse. Of these, 68.4% were treated for more than 1 year and 36.8% were treated for 2 years after achieving quiescence with a median time of 1.73 years (Interquartile range: 0.25-2.15) from inactive disease to drug discontinuation. There was an increased risk for failure on adalimumab versus infliximab [HR 13.4, (5% CI: 2.2-82.5), P ¼ 0.01] and in children older at uveitis diagnosis [HR 1.32, (95% CI 1.03-1.69), P ¼ 0.03]. Incidence of failure was not associated with additional immunomodulatory therapy, duration of suppression, sex, race, diagnosis, time from diagnosis to drug initiation, or uveitis severity at drug initiation. The probability of a uveitis reactivation after discontinuation of TNFi was estimated at 18% by 3 months, 38% by 6 months, and 55% by 9 months with the median time to failure of 3.9 months. Thus younger children at diagnosis and treated with infliximab may have an increased chance of remission. However, others have shown that adalimumab is superior to infliximab [45 && ]. In addition, half will relapse before 1 year after discontinuation of drug.
Measurement of uveitis outcomes
Accurate measurement of the impact of disease and treatment on a child's daily life is crucial. We rely on the clinical ocular exam, specifically visual acuity, as a proxy for visual function; the number of anterior chamber cells from the standardization of uveitis nomenclature criteria as a measure of disease activity; and the presence of complications as a measure of tissue damage [46] . Uveitis studies often overlook the child's perspective on disease and treatment burden, as well as the holistic effects of visual disability. There is a general consensus that incorporating patient reported outcome (PRO) measures improves our understanding of the interaction between disease and quality of life (QOL). Of 94 studies on medication efficacy in adults with uveitis, none included PROs but focused on uveitis activity (74%), visual acuity (52%), and tissue damage (4%) [47] . For children, there is a paucity of vision-specific pediatric QOL instruments [48] .
The first uveitis-specific instrument, the effects of youngsters' eyesight on QOL (EYE-Q), was developed and validated in children with normal vision, various ocular disorders, JIA, and uveitis [49,50,51 & ]. Total 57 children (eight JIA, 24 JIAuveitis, 25 uveitis alone) were administered the EYE-Q; 102 ocular examinations were performed within 1 month of completing the EYE-Q and the Pediatric Quality of Life Inventory (PedsQL), a general QOL assessment [49] . Children with vision loss in their better eye (visual acuity 20 of 50) had worse vision-related function and overall QOL as measured by the EYE-Q (P ¼ 0.002) and PedsQL (P ¼ 0.028). However, correlations between these measures and visual acuity, a proxy of visual function, showed that the EYE-Q moderately correlated with Logarithm of the minimum angle of resolution visual acuity (r s ¼ À0.43), whereas the PedsQL did not. Hence, the EYE-Q appears to be a valid and reliable measure of vision-related function in association with visual acuity. The PedsQL failed to show variation in QOL based on visual acuity, underlining the importance of a uveitisspecific measure.
CONCLUSION
Early identification of children at greatest risk for uveitis and targeted treatment may improve visual outcomes. This review provides information on risk factors for uveitis development and a severe course that considers clinical and genetic risk factors and novel biomarkers. We describe treatment of refractory disease, and provide data on the epidemiology of disease related to medication use. In addition, we discuss the importance of PROs, and describe a uveitis-specific tool. && Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis-associated uveitis: results from a pilot study. Invest Ophthalmol Vis Sci 2015; 56:7653-7660. The reports on elevated S100 subtypes S100A8/A9 and S100A12 levels in both serum and AqH of a large cohort of children with varied forms of autoimmune uveitis. This may be a potential biomarker for uveitis in children with inactive arthritis.
